Shares of Agenus Inc (NASDAQ: AGEN), a
company engaged in the development and commercialization of technologies to
treat cancers and infectious diseases, recorded over 16% gains during each of
the past two consecutive trading sessions, with a significant number of shares
exchanging hands. AGEN was one of the top performers in the U.S healthcare sector after gaining 16.6% and closed at $6.17 Monday, while recording significant trading volumes of 27.6 million shares. The share price rose due to the recent announcement made by the company about its global alliance with Incyte Corporation (Nasdaq: INCY) to develop Novel Immuno-Oncology Antibodies. During the past 5-trading sessions, AGEN gained 47.9% with daily average trading volumes of 1.1 million shares, while the stock accumulated 91.6% gain during the past one month with daily average trading volumes of 2.6 million shares. The stock is up 55.4% year-to-date.
Company Description:
Agenus, Inc. (NASDAQ: AGEN) develops vaccines. The company researches vaccines for brain cancer, kidney cancer, herpes, lung cancer, melanoma, malaria, shingles, and Alzheimer’s disease.
1-Year Stock Chart:
Source: Bloomberg
